Kolumnen und Serien
Beiträge zum Schlagwort:
Neoadjuvant nivolumab safe in resectable NSCLC
Neoadjuvant nivolumab was safe, and yielded pathologic responses in patients with resectable lung cancer.
Drew Pardoll on neoadjuvant nivolumab in stage 1-3 NSCLC
The neoadjuvant PD-1 blockade in resectable lung cancer led to major pathological responses in 45 percent of the patients enrolled in a clinical trial.
Leena Gandhi on the results of KEYNOTE-189
In the study, the combination of chemotherapy with pembrolizumab performed significantly better in terms of ORR, PFS and OS.
First-line pembro + chemo improved survival in KEYNOTE-189
KEYNOTE-189 met its dual primary endpoints of overall survival and progression-free survival in newly diagnosed metastatic NSCLC.
Improved PFS with nivo + ipi in patients with advanced NSCLC with high TMB
Patients with newly diagnosed advanced NSCLC with high tumor mutational burden had significantly improved PFS with nivolumab plus ipilimumab.